Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Coliseum Capital and Bioscrip Inc. (BIOS)

Page 1 of 10

Bioscrip Inc. (NASDAQ:BIOS): Christopher Shackelton And Adam Gray’s Coliseum Capital filed an amended 13D.

You can check out Coliseum Capital’s latest holdings and filings here.

Please follow Coliseum Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Coliseum Capital or update its stock holdings.

Christopher Shackelton And Adam Gray
Christopher Shackelton And Adam Gray
Coliseum Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Coliseum Capital Management 0 21,514,620 0 21,514,620 21,514,620 14.6%
Coliseum Capital 8. 16,548,264 0 16,548,264 16,548,264 11.6%
Coliseum Capital Partners 0 13,522,621 0 13,522,621 13,522,621 9.7%
Coliseum Capital Partners II 0 3,025,643 0 3,025,643 3,025,643 2.3%
Adam Gray 0 21,514,620 0 21,514,620 21,514,620 14.6%
Christopher Shackelton 0 21,514,620 0 21,514,620 21,514,620 14.6%
Christopher Shackelton And Adam Gray
Christopher Shackelton And Adam Gray
Coliseum Capital

Page 1 of 10 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE
13D/A

Under the Securities Exchange Act of 1934*

(Amendment No. 5)

 

 

BioScrip,
Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

09069N108

(CUSIP Number)

Christopher Shackelton/Adam Gray

105 Rowayton Ave.

Rowayton, CT 06853

(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 7, 2017

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of sections 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box.   ☐

The information required on the remainder of
this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).

Page 1 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!
Page 1 of 10